Business
BUSINESS Overview Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies.
Entera Bio Ltd.: Revenue declined 76.8% to $42K from $181K. Net loss widened to $11.44M from $9.541M. Free cash flow outflow widened to $7.477M from $6.821M. Operating margin contracted 2215442 bps to -27450.00%. Entera Bio Ltd.'s annual comparison also shows stock compensation grew faster than revenue; capital spending grew faster than revenue; the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is grey.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 76.8% to $42K from $181KWatch
- Profitability — Net loss widened to $11.44M from $9.541MWatch
- Cash flow — Free cash flow outflow widened to $7.477M from $6.821MWatch
- Margins — Operating margin contracted 2215442 bps to -27450.00%Watch
- Accounting — Going-concern warningWatch
- Insiders — 8 purchases and 0 salesOK
Leadership changes
From Entera Bio Ltd.'s own filings, the day they're filed.
- Geno J. Germano · director · appointmenteff. 2026-02-04
- Gerald Lieberman · Chairman · departureeff. 2026-02-04
- Steven D. Rubin · Director · appointmenteff. 2026-02-01
Latest filings
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-07
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-07-16
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Entera Bio Ltd., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.